

NICORISCOVID - Measurement of the strength of the relationship between tobacco use and the RT-PCR test for SARS-CoV2

Head :KARMOCHKINE Marina, no

Last update : 05/05/2021 | Version : 1 | ID : 73679

General	
Identification	
Detailed name	Measurement of the strength of the relationship between tobacco use and the RT-PCR test for SARS-CoV2
Sign or acronym	NICORISCOVID
CNIL registration number, number and date of CPP agreement, AFSSAPS (French Health Products Safety Agency) authorisation	APHP200663
General Aspects	
Medical area	Infectious diseases
Study in connection with Covid-19	Yes
Health determinants	Lifestyle and behavior
Keywords	tobacco nicotine Covid
Scientific investigator(s) (Contact)	
Name of the director	KARMOCHKINE
Surname	Marina
Address	Service ImmunoInfectieux Hôtel Dieu Place du Parvis Notre Dame 75004 Paris
Phone	142348469
Email	marina.karmochkine@aphp.fr
Unit	no

Organization	AP-HP
Collaborations	
Participation in projects, networks and consortia	No
Funding	
Details	no funding
Governance of the database	
Sponsor(s) or organisation(s) responsible	AP-HP
Organisation status	Public
Presence of scientific or steering committees	Yes
Labelling and database evaluation	Paris Descartes CRU/CIC
Additional contact	
Email	yannick.vacher@aphp.fr
Main features	
Type of database	
Type of database	Study databases
Study databases (details)	Case control study
Database recruitment is carried out by an intermediary	A population file
Database recruitment is made on the basis of:	Another treatment or procedure
Database recruitment is carried out as part of an interventional study	Yes
Details	Performed at individual level
Additional information regarding sample selection.	Healthcare professionals having attended the Hôtel Dieu Covid screening centre in March-April 2020, tested by nasal SARS CoV2 PCR CASES: PCR+

CONTROLS: PCR-

Database objective	
Main objective	Measure the strength of the relationship between tobacco use and the RT-PCR test for SARS-CoV2
Inclusion criteria	Care personnel having attended the Hôtel-Dieu Hospital Covid screening centre for symptoms compatible with SARS-CoV2 infection, -Aged over 18 years, With an email address, -Able to express non-objection (=questionnaire feedback
Population type	
Age	Adulthood (19 to 24 years) Adulthood (25 to 44 years) Adulthood (45 to 64 years) Elderly (65 to 79 years)
Population covered	General population
Pathology	
Gender	Male Woman
Geography area	
French regions covered by the database	Île-de-France
Data collection	
Dates	
Date of first collection (YYYY or MM/YYYY)	2020
Date of last collection (YYYY or MM/YYYY)	2020
Size of the database	
Size of the database (number of individuals)	[1000-10 000[individuals
Details of the number of individuals	1000

Data

Database activity	Current data collection
-------------------	-------------------------

Type of data collected	Declarative data
------------------------	------------------

Declarative data (detail)	Internet self-questionnaire
---------------------------	-----------------------------

Details of collected declarative data	questionnaire consommation tabac et substituts nicotiniques au moment de la réalisation de la PCR SARS-Cov2
---------------------------------------	---

Presence of a biobank	No
-----------------------	----

Health parameters studied	Others
---------------------------	--------

Other (detail)	tobacco use and nicotine replacements
----------------	---------------------------------------

Procedures

Data collection method	Lime Survey anonymous questionnaire
------------------------	-------------------------------------

Participant monitoring	No
------------------------	----

Followed pathology	
--------------------	--

Links to administrative sources	No
---------------------------------	----

Promotion and access

Promotion

Access